Adjuvant medical therapy for prostate cancer.

Abstract:

IMPORTANCE OF THE FIELD:Prostate cancer is a common cancer and the role of adjuvant medical therapy continues to be investigated. An understanding of the use of adjuvant medical therapy is essential for the appropriate care of prostate cancer patients, especially for those with locally advanced or high-risk disease. AREAS COVERED IN THIS REVIEW:This article reviews the role of adjuvant treatment of non-metastatic prostate cancer. To identify all pertinent publications, a literature search of the National Library of Medicine (PubMed) from inception to 22 June 2010 was conducted for 'adjuvant prostate cancer', with these results filtered for clinical trials and systematic reviews. WHAT THE READER WILL GAIN:This work reviews the uses of adjuvant androgen deprivation therapy and chemotherapy for prostate cancer. There is a clear benefit from the use of androgen deprivation therapy in conjunction with radiation therapy for selected patients, but the role of postoperative chemotherapy is poorly defined. Identifying appropriate patients for adjuvant therapy continues to be a challenge. TAKE HOME MESSAGE:There is a complex literature describing the role of adjuvant medical therapy in prostate cancer, which is reviewed here. Continuing and future clinical trials will define the utility of adjuvant therapy in this setting and require the support of the clinical community.

authors

Sumey C,Flaig TW

doi

10.1517/14656566.2010.516252

subject

Has Abstract

pub_date

2011-01-01 00:00:00

pages

73-84

issue

1

eissn

1465-6566

issn

1744-7666

journal_volume

12

pub_type

杂志文章,评审
  • On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1524874

    authors: Samples LS,Graf SA

    更新日期:2018-10-01 00:00:00

  • Pharmacotherapy for the treatment of vaginal atrophy.

    abstract:INTRODUCTION:Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low dose estrogen product is the main th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1574752

    authors: Donders GGG,Ruban K,Bellen G,Grinceviciene S

    更新日期:2019-05-01 00:00:00

  • Vinflunine for the treatment of breast cancer.

    abstract:INTRODUCTION:Breast cancer is the most frequently diagnosed cancer and the highest cause of cancer mortality in females worldwide. The development of drugs improving overall survival in late-stage metastatic breast cancer remains a challenge. Vinflunine is the most recently developed drug in the vinca alkaloid class. I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1217991

    authors: Gourmelon C,Bourien H,Augereau P,Patsouris A,Frenel JS,Campone M

    更新日期:2016-09-01 00:00:00

  • Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis.

    abstract:AIM:To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies. METHODS:The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/14656566.2017.1400011

    authors: Cai X,Gao X,Yang W,Ji L

    更新日期:2017-12-01 00:00:00

  • Opioids in the treatment of postoperative pain: old drugs with new options?

    abstract::New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2014.879292

    authors: Raeder J

    更新日期:2014-03-01 00:00:00

  • Apomorphine in the treatment of Parkinson disease and other movement disorders.

    abstract:BACKGROUND:Apomorphine, a medication that has been studied intensively over the years, is available in the US as intermittent subcutaneous injections for treatment of 'off' motor states in Parkinson disease. OBJECTIVE:The clinical literature is summarized with particular focus on randomized controlled studies of apomo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902828344

    authors: Gunzler SA

    更新日期:2009-04-01 00:00:00

  • Novelties in the multifaceted miconazole effects on skin disorders.

    abstract:BACKGROUND:Miconazole nitrate is a time-honored antifungal of the imidazole class. OBJECTIVE:To revisit the various aspects of action of the drug in a dermatologic setting. METHOD:Review of the current peer-reviewed publications. RESULTS/CONCLUSION:Miconazole essentially inhibits 14alpha-demethylase, an enzyme requi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.11.1927

    authors: Quatresooz P,Vroome V,Borgers M,Cauwenbergh G,Piérard GE

    更新日期:2008-08-01 00:00:00

  • Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.

    abstract:INTRODUCTION:Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369956

    authors: Flynn MJ,Larkin JMG

    更新日期:2017-10-01 00:00:00

  • Varicella zoster: an update on current treatment options and future perspectives.

    abstract:INTRODUCTION:Varicella zoster virus is a highly contagious virus that causes a primary infection known as varicella (chickenpox) that may reactivate years later to cause herpes zoster (HZ or shingles). After shingles heal, patients may develop post-herpetic neuralgia (PHN), neuropathic pain syndrome that can cause sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.860443

    authors: Kim SR,Khan F,Ramirez-Fort MK,Downing C,Tyring SK

    更新日期:2014-01-01 00:00:00

  • Chemoradiotherapy for lung cancer.

    abstract::Chemoradiotherapy is a standard treatment for both unresectable locally advanced non-small cell lung cancer and limited-stage small cell lung cancer. Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced non...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.16.2793

    authors: Ohe Y

    更新日期:2005-12-01 00:00:00

  • Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study.

    abstract::Pancreatic cancer has one of the worst prognosis of any malignant disease. Systemic therapy is often administered because the disease is usually detected at advanced stages. Gemcitabine (Gemzar trade mark, Eli Lilly & Co.) has proven activity in the treatment of pancreatic cancer. Gemcitabine 1000 mg/m(2) was given on...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.4.581

    authors: Karasek P,Skacel T,Kocakova I,Bednarik O,Petruzelka L,Melichar B,Bustova I,Spurny V,Trason T

    更新日期:2003-04-01 00:00:00

  • Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.

    abstract:BACKGROUND:Fesoterodine is a newly approved drug for the treatment of overactive bladder syndrome. OBJECTIVE:The aim of this study was to review the preclinical and clinical data on fesoterodine. METHODS:The study involved a search of the Medline database and the proceedings volumes of urological congresses. RESULTS...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.10.1787

    authors: Michel MC

    更新日期:2008-07-01 00:00:00

  • Advances in pharmacotherapy for hyperphosphatemia in renal disease.

    abstract:INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1092521

    authors: Spasovski G

    更新日期:2015-01-01 00:00:00

  • Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

    abstract:INTRODUCTION:Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia. AREAS COVERED:The effec...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.557359

    authors: Rizzo M,Corrado E,Patti AM,Rini GB,Mikhailidis DP

    更新日期:2011-03-01 00:00:00

  • Advances in orally administered pharmacotherapy for the treatment of migraine.

    abstract:INTRODUCTION:Migraine is a common and highly disabling neurological disorder whose acute treatment remains problematic and unsatisfactory in a high percentage of cases. Consequently, there remains a need for new symptomatic therapies that can be easily handled by patients (i.e. by oral administration). AREAS COVERED:T...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1549223

    authors: Martelletti P,Giamberardino MA

    更新日期:2019-02-01 00:00:00

  • Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.

    abstract:BACKGROUND:Patients with rheumatoid arthritis (RA) have an increased risk of atherosclerotic cardiovascular disease which cannot be explained by traditional cardiovascular risk factors alone. Atherosclerosis is considered an inflammatory condition and inflammation experienced in RA may contribute to accelerated atheros...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.7.1121

    authors: Avouac J,Allanore Y

    更新日期:2008-05-01 00:00:00

  • The use of retinoids in the prevention and treatment of skin cancer.

    abstract::There has been a significant increase in the number of cases of skin cancer diagnosed in the US in the past few years. Thus, it seems appropriate to review the available compounds that might be used in the chemoprevention of these lesions. This review focuses on the retinoids and details their results in clinical tria...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.3.299

    authors: Niles RM

    更新日期:2002-03-01 00:00:00

  • Adjunctive strategies in the treatment of refractory bipolar depression: clinician options in the absence of a systematic database.

    abstract::Multiple approaches to enhancing antidepressant treatment response in bipolar depression are available and should, in many instances, be explored despite a lack of definitive controlled trial literature supporting their efficacy. Given that the morbidity of depression is three times greater than mania in bipolar illne...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.4.531

    authors: Post RM

    更新日期:2005-04-01 00:00:00

  • Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.

    abstract::HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is presently the most common long-term adverse effect limiting the doubtless efficacy of antiretroviral therapy. It has a great impact on the quality of life of patients, it is stigmatising and its psychologically devastating consequen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.12.1871

    authors: del Mar Gutierrez M,Mateo G,Domingo P

    更新日期:2007-08-01 00:00:00

  • Paracetamol and asthma.

    abstract::Paracetamol (acetaminophen) is one of the over-the-counter analgesics that is used frequently for the self-management of some of the common disorders. There seems to be two types of relations between paracetamol and asthma - paracetamol intolerance leading to bronchospasm in analgesic-induced asthmatics; and the relat...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.1.13

    authors: Karakaya G,Kalyoncu AF

    更新日期:2003-01-01 00:00:00

  • Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.

    abstract:INTRODUCTION:Many patients with type 2 diabetes mellitus (T2DM) fail to achieve the desired A1c goal because the antidiabetic medications used do not correct the underlying pathophysiologic abnormalities and monotherapy is not sufficiently potent to reduce the A1c to the 6.5 - 7.0% range. Insulin resistance and islet (...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1114098

    authors: Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA

    更新日期:2015-01-01 00:00:00

  • Several options for antiviral treatment trials in multiple sclerosis--but which targets should be selected?

    abstract::Involvement of viruses in the pathogenesis of multiple sclerosis (MS) is a long-lived hypothesis, which is has not yet been proven nor refuted. This is partly due to difficulties in the evaluation of diagnostic findings on persistent infections by common viruses such as herpesviruses and endogenous retroviruses. Progr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.6.1087

    authors: Bergström T

    更新日期:2000-09-01 00:00:00

  • Neoadjuvant or adjuvant chemotherapy in early breast cancer?

    abstract:INTRODUCTION:The administration of chemotherapy before (neoadjuvant), rather than after surgery (adjuvant) in early breast cancer has been considered an optional strategy for patients with operable breast cancer. We reviewed this concept considering recent results in the field. AREAS COVERED:Herein, the authors cover ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1746273

    authors: Montemurro F,Nuzzolese I,Ponzone R

    更新日期:2020-06-01 00:00:00

  • Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.

    abstract:INTRODUCTION:Postprandial hyperglycemia (PPHG) contributes to micro- and macro-vascular complications more than fasting hyperglycemia in patients with type 2 diabetes mellitus. Due to the traditional carbohydrate-rich diet, Asians, particularly Indians and Chinese need agents to control the higher risk of uncontrolled ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1070827

    authors: Joshi SR,Standl E,Tong N,Shah P,Kalra S,Rathod R

    更新日期:2015-01-01 00:00:00

  • Management of bone mineral density in HIV-infected patients.

    abstract:INTRODUCTION:Loss of bone mineral density is an emerging problem in persons living with HIV infection. Earlier and more rapid bone demineralization has been attributed not only to the high prevalence of traditional risk factors, but also to specific HIV-related factors. The aim of this guidance is to stimulate an appro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1146690

    authors: Negredo E,Bonjoch A,Clotet B

    更新日期:2016-01-01 00:00:00

  • Current and future treatments of alopecia areata and trichotillomania in children.

    abstract:INTRODUCTION:Treatment options for hair disorders are generally very limited. These options are even more limited in children due to the lack of trials and clinical research. Moreover, physicians are sometimes scared to treat children with drugs without safety data, especially because most hair disorders are benign. A...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1217990

    authors: Iorizzo M,Oranje AP

    更新日期:2016-09-01 00:00:00

  • Pharmacological treatment of generalized anxiety disorder.

    abstract:INTRODUCTION:Generalized anxiety disorder (GAD) is a chronic, relapsing, debilitating disorder, associated with markedly impaired social and occupational functioning. Pharmacological treatment is considered standard care and several drug classes are now FDA approved for the treatment of GAD. While there are clear data ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.618496

    authors: Reinhold JA,Mandos LA,Rickels K,Lohoff FW

    更新日期:2011-11-01 00:00:00

  • Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review.

    abstract::Introduction: The current recommendations of chronic obstructive pulmonary disease (COPD) suggest to escalate from inhaled corticosteroid/long-acting β2-adrenoceptor agonist (ICS/LABA) treatment to triple therapy in patients experiencing persistent breathlessness, exercise limitation, or exacerbation. The addition of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1845314

    authors: Ritondo BL,Puxeddu E,Calzetta L,Cazzola M,Rogliani P

    更新日期:2020-11-11 00:00:00

  • Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.

    abstract:INTRODUCTION:Irritable bowel syndrome (IBS) treatment is challenging physicians because of its multifactorial physiopathology. In particular, abdominal pain and diarrhea management lack one unique effective pharmacological remedy. Opioid receptors, present in the central nervous system (CNS) and the enteric nervous sys...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1182982

    authors: Scarpellini E,Laterza L,Ianiro G,Tack J,Abenavoli L,Gasbarrini A

    更新日期:2016-07-01 00:00:00

  • Treatment advances in non-Hodgkin's lymphoma.

    abstract::Non-Hodgkin's lymphomas (NHL) encompass a heterogeneous group of lymphoid malignancies with varying natural histories and prognoses. Recent classifications for NHL have defined distinct lymphoma entities based on morphology, immunophenotype, genetic features, clonal cell lineage and clinical features. These new, more ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.3.451

    authors: Tan BR,Bartlett NL

    更新日期:2000-03-01 00:00:00